Insight Molecular Diagnostics Inc. (IMDX) Form 8-K — Sep 21, 2026
Insight Molecular Diagnostics (IMDX) entered Amendment No. 2 to its 2021 Chronix Biomedical merger agreement on September 15, 2026, restructuring the earnout obligations owed to Chronix's former equity holders. The amendment was executed with David MacKenzie, the equityholder representative, and disclosed via an 8-K filed September 21, 2026. Under the new terms, Chronix equity holders receive a 10% royalty on net collected sales of CNI Monitor, Company Pharma Tests, and Company Transplant IP, payable solely in cash.
Key figures
- Payment Form
- cash only
- Cni Monitor Royalty Rate
- 10% of net collected sales
- Cni Monitor Sale Payment
- 10% of gross proceeds
- Pharma Test Royalty Rate
- 10% of net collected sales
- Amendment Effective Date
- 2026-09-15
- Transplant IPRoyalty Rate
- 10% of net collected sales
- Transplant IPSale Payment
- 5% of gross proceeds
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.